BRIEF-Ironwood Pharmaceuticals Provides Clinical And Regulatory Update On Apraglutide

Reuters

14 Apr

BRIEF-Ironwood Pharmaceuticals Provides Clinical And Regulatory Update On Apraglutide

April 14 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O:

IRONWOOD PHARMACEUTICALS PROVIDES CLINICAL AND REGULATORY UPDATE ON APRAGLUTIDE
IRONWOOD PHARMACEUTICALS INC - ENGAGES GOLDMAN SACHS TO EXPLORE STRATEGIC ALTERNATIVES
IRONWOOD PHARMACEUTICALS INC - REQUIRES CONFIRMATORY PHASE 3 TRIAL FOR APRAGLUTIDE APPROVAL
IRONWOOD PHARMACEUTICALS INC - TO WORK WITH FDA ON CONFIRMATORY PHASE 3 TRIAL DESIGN

Source text: ID:nBw4hPKwZa

Further company coverage: IRWD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2527153820"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527153820\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2527153820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-14 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527153820","market":"us","top_or_hot":-1,"title":"BRIEF-Ironwood Pharmaceuticals Provides Clinical And Regulatory Update On Apraglutide","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Ironwood Pharmaceuticals Provides Clinical And Regulatory Update On Apraglutide</title></head><body><p><span>April 14 (Reuters)</span><span> - </span>Ironwood Pharmaceuticals Inc <span>IRWD.O</span>:</p><ul><li><p>IRONWOOD PHARMACEUTICALS PROVIDES CLINICAL AND REGULATORY UPDATE ON APRAGLUTIDE</p></li><li><p>IRONWOOD PHARMACEUTICALS INC - ENGAGES GOLDMAN SACHS TO EXPLORE STRATEGIC ALTERNATIVES</p></li><li><p>IRONWOOD PHARMACEUTICALS INC - REQUIRES CONFIRMATORY PHASE 3 TRIAL FOR APRAGLUTIDE APPROVAL</p></li><li><p>IRONWOOD PHARMACEUTICALS INC - TO WORK WITH FDA ON CONFIRMATORY PHASE 3 TRIAL DESIGN</p></li></ul><p>Source text: <span>ID:nBw4hPKwZa</span></p><p>Further company coverage: <span>IRWD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ironwood Pharmaceuticals Provides Clinical And Regulatory Update On Apraglutide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ironwood Pharmaceuticals Provides Clinical And Regulatory Update On Apraglutide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-14 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Ironwood Pharmaceuticals Provides Clinical And Regulatory Update On Apraglutide</title></head><body><p><span>April 14 (Reuters)</span><span> - </span>Ironwood Pharmaceuticals Inc <span>IRWD.O</span>:</p><ul><li><p>IRONWOOD PHARMACEUTICALS PROVIDES CLINICAL AND REGULATORY UPDATE ON APRAGLUTIDE</p></li><li><p>IRONWOOD PHARMACEUTICALS INC - ENGAGES GOLDMAN SACHS TO EXPLORE STRATEGIC ALTERNATIVES</p></li><li><p>IRONWOOD PHARMACEUTICALS INC - REQUIRES CONFIRMATORY PHASE 3 TRIAL FOR APRAGLUTIDE APPROVAL</p></li><li><p>IRONWOOD PHARMACEUTICALS INC - TO WORK WITH FDA ON CONFIRMATORY PHASE 3 TRIAL DESIGN</p></li></ul><p>Source text: <span>ID:nBw4hPKwZa</span></p><p>Further company coverage: <span>IRWD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nTUA7PN23K:1","article_id":"2527153820","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527153820","pubTimestamp":1744628866,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Ironwood Pharmaceuticals Provides Clinical And Regulatory Update On ApraglutideApril 14 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O:IRONWOOD PHARMACEUTICALS PROVIDES CLINICAL AND REGULATORY ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简介-Ironwood Pharmaceuticals提供阿普鲁肽的临床和监管更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRWD":0.9},"content_text":"BRIEF-Ironwood Pharmaceuticals Provides Clinical And Regulatory Update On ApraglutideApril 14 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O:IRONWOOD PHARMACEUTICALS PROVIDES CLINICAL AND REGULATORY UPDATE ON APRAGLUTIDEIRONWOOD PHARMACEUTICALS INC - ENGAGES GOLDMAN SACHS TO EXPLORE STRATEGIC ALTERNATIVESIRONWOOD PHARMACEUTICALS INC - REQUIRES CONFIRMATORY PHASE 3 TRIAL FOR APRAGLUTIDE APPROVALIRONWOOD PHARMACEUTICALS INC - TO WORK WITH FDA ON CONFIRMATORY PHASE 3 TRIAL DESIGNSource text: ID:nBw4hPKwZaFurther company coverage: IRWD.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}